TOP STORIES
Citron remains the kingmaker – or, more accurately, the coup-maker – in the second half of 2015. Its tweet sent Mallinckrodt’s shares falling.
At these prices $MNK has signif more downside than $VRX— far worse offender of the reimb sys – more to follow. VRX can’t live in a vacuum
— Citron Research (@CitronResearch) November 9, 2015
When Investment Rhymes with Canada
Canada has a proud history of achievement in the areas of science and technology, and the field of biomanufacturing and life sciences is no exception.
Does it prove there’s a bubble in the type of Valeant, Mallinckrodt-style business models and the backlash against high-price drugs is here to stay? Or does this prove public-markets investors are sheep? We’ll know more on Nov. 23, when earnings come out. – Financial Times, Bloomberg & MarketWatch
LIFE SCIENCES
AstraZeneca got good news on its would-be $1 billion lupus treatment anifrolumab. A mid-stage trial showed promise and AZ is moving on to a Phase III trial. – Reuters
Astellas Pharma will buy Ocata Therapeutics in an all-cash deal worth $379 million. – Xconomy
Vision Medicines has raised enough money for a first trial in its Stargardt disease treatment. – Xconomy
Aminex Therapeutics closed $4 million to advance its cancer immunotherapy treatment. – PR Newswire
ReliantHeart, which makes a left ventricular assist device, has raised on $2 million and could raise up to $14 million more. – Houston Business Journal
Eli Lilly’s diabetes treatment Jardiance helped type 2 diabetes patients cut the risk of heart-related death and other issues. – Reuters
PAYERS-PROVIDERS
Patients listen to advice based on their genetics – at least when it comes to heart disease. – Reuters
GE Healthcare has acquired The Camden Group. – Modern Healthcare
I like this article on patient simulators but it doesn’t have a single statistic or reference a single research study proving more realistic mannequins are cutting down on young doctors’ medical mistakes. Have you every seen one? – The New York Times
TECHNOLOGY
Two interesting insights on ResearchKit: the unique innovation of informed consent and its integration into apps for clinical research. – MobiHealthNews & Triangle Business Journal
Dorado Systems, which builds technology to connect the systems of payers and providers, has raised $8 million. – Philadelphia Business Journal
FitBit has a secondary offering that will largely help existing shareholders get liquid. – 247WallStreet
Patient-registration and management service Cureatr has expanded further in New York state. – Albany Business Review
Parenting app Baby Bundle raised nearly $2 million. – PE Hub
Dr. Peter Tippett, most recently the Verizon chief medical officer, has joined DataMotion’s board. – PR Newswire
A LITTLE BIT EXTRA
Trying to wrap your head around the state of race issues on college campus through the resignation of Missouri’s president? Oddly enough, a sports blog and The New York Times are delivering the most insight. – Deadspin & The New York Times
Photo: Flickr user James Barwell
